The first identification of a role for TSLP in cancer was in pancreatic (23) and breast cancers (24, 25), in which TSLP, secreted by either CAFs or tumor cells, respectively, was found to exert tumor-promoting functions through the establishment of predominant Th2-type inflammation in the tumor microenvironment. Here, TSLP is linked to breast carcinoma.